Aseptika recently announced that it has been granted a United States patent protecting the company’s proprietary respiratory infection test — the Sputum test — which is designed to significantly benefit those with chronic and debilitating pulmonary conditions, such as COPD.

The test was designed to be utilized by clinicians in hospitals and by patients themselves at home. This technology determines the amount of activity of the bacteria in the lungs of patients that are vulnerable because of long-term conditions like Cystic Fibrosis, COPD and Asthma.